Investing.com– Shares in Intra-Cellular Therapies (NASDAQ:) surged in premarket trading on Monday on a report that Johnson & Johnson (NYSE:) is considering a bid to acquire the biopharmaceutical company.

Citing sources familiar with the matter, Bloomberg News reported that a deal between both parties could be reached as early as this week. Intra-Cellular has a market value of roughly $10 billion.

The discussions are said to be in an early stage, and no final decision has been made, the report said, adding that there is no guarantee the negotiations will lead to a formal deal.ย 

Intra-Cellular Therapies is best known for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. The potential acquisition could help J&J expand its neuroscience portfolio and offset revenue challenges anticipated from patent expirations on its blockbuster drugs.

J&J has remained active in pursuing high-growth therapeutic areas, aiming to solidify its pharmaceutical divisionโ€™s growth amidst intensifying competition.

Intra-Cellular shares jumped by more than 33% ahead of the start of US trading. The stock rose nearly 15% on Friday.ย 

(Ayushman Ojha contributed reporting.)

ย 


Source link

Best Brokers

Unmatched trading fees, generous bonuses, top notch Regulation Frame.

T&Cs Apply

Risk disclosure: All investments involve a degree of risk of some kind. Trading financial derivative products comes with a high risk of losing money rapidly due to leverage.

Top-Tier Regulations. Unmatched Spreads and Commissions. Trading View is available.

T&Cs Apply

Financial Spread Trades and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84.7% of retail investor accounts lose money when trading CFDs with this provider.

Modern and Intuitive Interfaces, Solid Regulatory Frame, and excellent Trading Fees.

T&Cs Apply
Risk warning: Trading derivatives is highly speculative, carries an inherent risk of loss and is not suitable for all investors. Before trading, you are strongly advised to read and ensure that you understand the relevant risk disclosures and warnings.

Highly Regulated. Low Spreads and Commissions. Vast Account Options.

T&Cs Apply

Risk Warning: Trading derivatives carries significant risks. It is not suitable for all investors and if you are a professional client, you could lose substantially more than your initial investment.